Literature DB >> 11962761

Tumor-associated fibroblasts (part I): Active stromal participants in tumor development and progression?

L A Kunz-Schughart1, R Knuechel.   

Abstract

Phenotypic and functional characteristics of tumor associated fibroblasts (TAF) in contrast to normal fibroblasts are reviewed in this first synopsis (part I). Terms as tumor stroma, desmo-plasia, TAF, myofibroblast, and fetal-type fibroblast are defined, and experimental systems to study heterologous cell interactions are presented. While we only start to gather information on the genotype of TAF, a broad range of data deals with the expression profile of these cells, covering e.g. ECM and ECM-modulating molecules, growth factors and cytokines. Summarizing the recent state of knowledge indicates that TAF provide sources for tumor diagnosis and therapy, that have to be further defined in an organ-specific approach in terms of the functional impact on the tumor cell and its environment (see part II).

Entities:  

Mesh:

Year:  2002        PMID: 11962761     DOI: 10.14670/HH-17.599

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  64 in total

Review 1.  Physico-mechanical aspects of extracellular matrix influences on tumorigenic behaviors.

Authors:  Edna Cukierman; Daniel E Bassi
Journal:  Semin Cancer Biol       Date:  2010-05-07       Impact factor: 15.707

2.  VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis.

Authors:  Jianying Dong; Jeremy Grunstein; Max Tejada; Frank Peale; Gretchen Frantz; Wei-Ching Liang; Wei Bai; Lanlan Yu; Joe Kowalski; Xiaohuan Liang; Germaine Fuh; Hans-Peter Gerber; Napoleone Ferrara
Journal:  EMBO J       Date:  2004-07-01       Impact factor: 11.598

3.  Induction of lung epithelial cell transformation and fibroblast activation by Yunnan tin mine dust and their interaction.

Authors:  Li Bian; Yong-Wen He; Rui-Zhu Tang; Li-Ju Ma; Chun-Yan Wang; Yong-Hua Ruan; Qian Gao; Ke-Wei Jin
Journal:  Med Oncol       Date:  2010-08-18       Impact factor: 3.064

Review 4.  Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles.

Authors:  Brett Hall; Jennifer Dembinski; A Kate Sasser; Matus Studeny; Michael Andreeff; Frank Marini
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

5.  Carcinogenesis and metastasis now in the third dimension--what's in it for pathologists?

Authors:  Carlos Sonnenschein; Ana M Soto
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

6.  Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers.

Authors:  Giulia Grisendi; Rita Bussolari; Elena Veronesi; Serena Piccinno; Jorge S Burns; Giorgio De Santis; Pietro Loschi; Marco Pignatti; Fabrizio Di Benedetto; Roberto Ballarin; Carmela Di Gregorio; Valentina Guarneri; Lino Piccinini; Edwin M Horwitz; Paolo Paolucci; Pierfranco Conte; Massimo Dominici
Journal:  Am J Cancer Res       Date:  2011-05-28       Impact factor: 6.166

7.  Muscularis mucosae in desmoplastic stroma formation of early invasive rectal adenocarcinoma.

Authors:  Shinichi Ban; Michio Shimizu
Journal:  World J Gastroenterol       Date:  2009-10-21       Impact factor: 5.742

8.  Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1.

Authors:  George S Karagiannis; Aaron Berk; Apostolos Dimitromanolakis; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2013-04-18       Impact factor: 6.603

Review 9.  Defining the Hallmarks of Metastasis.

Authors:  Danny R Welch; Douglas R Hurst
Journal:  Cancer Res       Date:  2019-05-03       Impact factor: 12.701

10.  Cell adhesion to the extracellular matrix protein fibronectin modulates radiation-dependent G2 phase arrest involving integrin-linked kinase (ILK) and glycogen synthase kinase-3beta (GSK-3beta) in vitro.

Authors:  N Cordes; D van Beuningen
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.